tafasitamab

Home
Ligands
tafasitamab

GtoPdb Ligand ID: 11131

Synonyms: Minjuvi® | Monjuvi® | MOR-208 | MOR00208 | MOR208 | tafasitamab-cxix | Xmab5574

tafasitamab is an approved drug (FDA (2020), EMA (2021))

Comment: Tafasitamab (MOR208, formerly Xmab®5574) is a humanized Fc-engineered monoclonal antibody directed against CD19 that was developed by MorphoSys [4]. XmAb® antibodies are designed with modifications in their Fc domain (S239D/I332E mutations) that increase binding to Fcγ receptors on immune cells. This optimises the antibody's Fc-mediated effector function (i.e. antibody-dependent cell-mediated cytotoxicity, ADCC) [1,5]. At the beginning ot 2020, MorphoSys and Incyte Corporation entered into a collaboration and license agreement for the global development and commercialization of tafasitamab (MOR208).

References
1. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM, Roda JM, Cheney C, Mo X, Lehman A et al.. (2010) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood, 115 (6): 1204-13. [PMID:19965644]
2. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R et al.. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res, 68 (19): 8049-57. [PMID:18829563]
3. Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S et al.. (2018) Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol, 29 (5): 1266-1272. [PMID:29444231]
4. Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M et al.. (2013) The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia, 27 (7): 1595-8. [PMID:23277329]
5. Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. (2012) XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia, 26 (7): 1720-2. [PMID:22333878]
6. Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M et al.. (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol, 21 (7): 978-988. [PMID:32511983]

References

1. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM, Roda JM, Cheney C, Mo X, Lehman A et al.. (2010)
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
Blood, 115 (6): 1204-13. [PMID:19965644]

2. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R et al.. (2008)
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Cancer Res, 68 (19): 8049-57. [PMID:18829563]

3. Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S et al.. (2018)
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Ann Oncol, 29 (5): 1266-1272. [PMID:29444231]

4. Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M et al.. (2013)
The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.
Leukemia, 27 (7): 1595-8. [PMID:23277329]

5. Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. (2012)
XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.
Leukemia, 26 (7): 1720-2. [PMID:22333878]

6. Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M et al.. (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol, 21 (7): 978-988. [PMID:32511983]